Evidence map›Paper›PMID 35681576›Full record

ArticleCancers2022

Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation.

Cristina Morelli, Michela Rofei, Silvia Riondino, Daniela Fraboni, Francesco Torino, Augusto Orlandi, Manfredi Tesauro, Giovanna Del Vecchio Blanco, Massimo Federici, Hendrik-Tobias Arkenau and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Cristina MorelliMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.
Michela RofeiMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.
Silvia RiondinoMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.
Daniela FraboniDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
Francesco TorinoMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.ORCID 0000-0001-5828-4438
Augusto OrlandiAnatomic Pathology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0001-7202-5854
Manfredi TesauroDepartment of Internal Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Giovanna Del Vecchio BlancoGastroenterology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-6327-563X
Massimo FedericiDepartment of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Hendrik-Tobias ArkenauSarah Cannon Research Institute, Cancer Institute, University College London, London W1G 6AD, UK.ORCID 0000-0002-2015-1549
Vincenzo FormicaMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.ORCID 0000-0002-5380-3144
Mario RoselliMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.ORCID 0000-0002-2431-6689
University of Rome Tor Vergata · ITSarah Cannon Research Institute · GB

Funding

European Union's Horizon 2020 research and innovation program "REVERT" No 848098
6 · The paper itself

Abstract

Background: Vitamin D deficiency is a poor prognostic factor in metastatic colorectal cancer (mCRC); however, targeted supplementation trials have so far yielded limited results. We investigated clinical-laboratory parameters influencing vitamin D deficiency, with a particular focus on immune response, and the effect on survival. These parameters could help optimize targeted supplementation therapy. Methods: Association of plasma 25-hydroxyvitamin D (25(OH])D) with overall survival (OS) was assessed with the Hazard Ratio Smoothed Curve with Restricted Cubic Splines (HRSC-RCS) and maximally selected rank statistics (MSRS) in mCRC patients who underwent first-line chemotherapy. Several hematobiochemical variables were evaluated as predictors of vitamin D deficiency by means of Least Absolute Shrinkage and Selection Operator (LASSO) analysis. In a patient subset, peripheral lymphocyte subpopulations were also analyzed. Results: One hundred thirty-three mCRC patients were included. The median(m) baseline 25(OH)D was 10.8 ng/mL (range 3−53.4). HRSC-RCS revealed a linear association between 25(OH)D and OS. MSRS found 10 ng/mL as the optimal 25(OH)D cut-off. The median OS for 25(OH)D < 10 (n = 60) vs. > 10 ng/mL (n = 73) was 12.3 and 24.5 months, respectively (p = 0.002). The LASSO analysis identified high neutrophil-to-lymphocyte ratio (NLR > 3.5) as the strongest predictor of vitamin D deficiency (Odds Ratio 3.35, p 0.0009). Moreover, patients with low 25(OH)D levels (< 10 ng/mL) and high NLR (>3.5) had the shortest survival and patients with 25(OH)D >10 ng/mL and NLR <3.5 had the longest: mOS 8.1 and 28.1 months, respectively, HR 3.40 (1.76−6.59), p 0.0004. Besides the significant difference in NLR between 25(OH)D < and > 10 ng/mL patients (mNLR 3.6 vs. 2.9, p 0.03), the lymphocyte subpopulation analysis revealed that vitamin D deficiency was associated with high T- CD4+ (p = 0.04) and low B (p = 0.03) lymphocyte frequency. Conclusions: NLR is a powerful predictor of Vitamin D deficiency and can further help in stratifying prognosis. Vitamin D deficiency was associated with significant variations in peripheral immune cells. We hypothesize that integrated targeted interventions to both vitamin D and immune system would improve the prognosis of mCRC patients.

Indexed as

colorectal cancerpredictive markerstargeted therapies

Identifiers

PMID35681576
PMCPMC9179512
OpenAlexW4281554922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.